Can HIV infection be eradicated through use of potent antiviral agents?

Current Opinion in Infectious Diseases

Volumn 23, Issue 6, 2010, Pages 628-632

  Josefsson, Lina ^a,b   Dahl, Viktor ^a,b   Palmer, Sarah ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

eradication; HIV latency; HIV reservoir; reactivation

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROSTATIN; PROTEINASE INHIBITOR; RALTEGRAVIR; UNCLASSIFIED DRUG; VALPROIC ACID; VIRUS DNA; VORINOSTAT;

CD34 SELECTION; CD4+ T LYMPHOCYTE; CELL ISOLATION; CPG ISLAND; CYTOPATHOGENIC EFFECT; DEACETYLATION; DNA METHYLATION; DNA MODIFICATION; DRUG PENETRATION; GUILLAIN BARRE SYNDROME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LATENT PERIOD; MEMORY T LYMPHOCYTE; NONHUMAN; REVIEW; VIREMIA; VIRUS IMMUNITY; VIRUS REACTIVATION; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; HIV; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; RNA, VIRAL; T-LYMPHOCYTE SUBSETS; VIREMIA; VIRUS ACTIVATION; VIRUS LATENCY; VIRUS REPLICATION;

EID: 78349311248     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32833ff1d0     Document Type: Review

References (28)

1. Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 2008; 105:3879-3884.
2. Dinoso JB, Kim SY, Wiegand AM, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci USA 2009; 106:9403-9408.
3. McMahon D, Jones J, Wiegand A, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 2010; 50:912-919.
4. Buzon MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010; 16:460-465.
5. Maldarelli F, PalmerS, King MS, et al. ART suppresses plasma HIV-1 RNAtoa stable set point predicted by pretherapy viremia. PLoS Pathog 2007; 3:e46.
6. Finzi D, HermankovaM, PiersonT, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-1300.
7. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997; 94:13193-13197.
8. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15:893-900.
9. Bailey JR, Sedaghat AR, Kieffer T, et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol 2006; 80:6441-6457.
10. Carter CC, Onafuwa-Nuga A, McNamara LA, et al. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med 2010; 16:446-451.
11. Mavigner M, Delobel P, Cazabat M, et al. HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS One 2009; 4:e7658.
12. Dahl V, Josefsson L, Palmer S. HIV reservoirs, latency, and reactivation: prospects for eradication. Antiviral Res 2010; 85:286-294.
13. Bosque A, Planelles V. Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood 2009; 113:58-65.
14. Tyagi M, Pearson RJ, Karn J. Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction. J Virol 2010; 84:6425-6437.
15. Yang HC, Xing S, Shan L, et al. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest 2009; 119:3473-3486.
16. Blazkova J, Trejbalova K, Gondois-Rey F, et al. CpG methylation controls reactivation of HIV from latency. PLoS Pathog 2009; 5:e1000554.
17. Kauder SE, Bosque A, Lindqvist A, et al. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog 2009; 5:e1000495.
18. Brady T, Agosto LM, Malani N, et al. HIV integration site distributions in resting and activated CD4+T cells infected in culture. AIDS 2009; 23:1461-1471.
19. Reuse S, Calao M, Kabeya K, et al. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One 2009; 4:e6093.
20. Burnett JC, Lim KI, Calafi A, et al. Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol 2010; 84:5958-5974.
21. Lehrman G, Hogue IB, Palmer S, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005; 366:549-555.
22. Archin NM, Espeseth A, Parker D, et al. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 2009; 25:207-212.
23. Contreras X, Schweneker M, Chen CS, et al. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem 2009; 284:6782-6789.
24. Yang HC, Shen L, Siliciano RF, Pomerantz JL. Isolation of a cellular factor that can reactivate latent HIV-1 without T cell activation. Proc Natl Acad Sci USA 2009; 106:6321-6326.
25. Dinoso JB, Rabi SA, Blankson JN, et al. A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol 2009; 83:9247-9257.
26. North TW, Higgins J, Deere JD, et al. Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol 2010; 84:2913-2922.
27. Lindkvist A, Eden A, Norstrom MM, et al. Reduction of the HIV-1 reservoir in resting CD4+ T-lymphocytes by high dosage intravenous immunoglobulin treatment: a proof-of-concept study. AIDS Res Ther 2009; 6:1 5.
28. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360:692-698.